Scaling back aid for Africa is a strategic misstep for the United States

Abstract

Policy shifts in US foreign aid under the Trump administration have had far-reaching consequences for global health, particularly on the African continent. The withdrawal from the World Health Organization and the suspension of foreign aid have significantly disrupted US global health initiatives. While programmes such as PEPFAR have retained some support, the shutdown on USAID operations–a critical agency for health and disease response across 47 sub-Saharan African countries–poses substantial challenges. These cutbacks not only threaten public health efforts but also diminish strategic investment opportunities, given Africa’s rapidly growing economies and potential for high economic returns. Furthermore, reducing aid endangers healthcare and biomedical innovations that have been instrumental in combating diseases such as Ebola and HIV. In the past, US-funded initiatives have contributed to Africa’s pharmaceutical manufacturing capacity and technological advancements, fostering mutual economic benefits. The shift in foreign aid policy risks weakening US global influence, creating a vacuum that geopolitical competitors, such as China and Russia, are poised to exploit. In this paper, we argue that sustained investment in African health initiatives is essential for strengthening economic partnerships, enhancing global health security, and reinforcing US geopolitical standing.